Synthesis and evaluation of 2-amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine mono- and diesters as potential prodrugs of ganciclovir

被引:7
作者
Kim, DK [1 ]
Chang, KY [1 ]
Im, GJ [1 ]
Kim, HT [1 ]
Lee, NK [1 ]
Kim, KH [1 ]
机构
[1] SK Chem, Life Sci Res Ctr, Suwon 440745, Kyungki Do, South Korea
关键词
D O I
10.1021/jm980321+
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 2-amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-floropurine mono- and diesters, 6a- h, were synthesized as potential prodrugs of ganciclovir and evaluated for their oral ganciclovir bioavailability in rats. Treatment of 2-amino-6-chloro-9-(1,3-dihydroxy-2-propoxymethyl)purine (4) with Me3N in DMF/THF (1/4) followed by the reaction of the resulting trimethylammonium chloride salt 5 with KF in DMF gave 2-amino-9-( 1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine (2) in 83% yield. Esterification of 2 with an appropriate acid anhydride (Ac2O, (EtCO)(2)O, (n-PrCO)(2)O, or (i-PrCO)(2)O) (6 equiv for 6a-d or 1 equiv for 6e-h) in DMF in the presence of a catalytic amount of DMAP produced the diesters 6a-d in 92-98% yields and the monoesters 6e-h in 37-44% yields. Of the prodrugs tested in rats, the monoisobutyrate 6h achieved the highest ganciclovir bioavailability (45%) that is 15-fold higher than that from ganciclovir (3%), followed in order by the diisobutyrate Sd (42%), the diacetate 6a (41%), the monobutyrate 6g (41%), the monopropionate 6f (39%), the dipropionate 6b (35%), the dibutyrate 6c (35%), and the monoacetate 6e (29%). The prodrugs 6e-h were found to be quite stable at pH 6.0 (t(1/2) = >29 days), 7.4 (t(1/2) =>7 days), and 8.0 (t(1/2) = >2 days) but had relatively short half-lives at pH 1.2 (t(1/2) = 60-83 min).
引用
收藏
页码:324 / 328
页数:5
相关论文
共 16 条
[1]  
ALFORD C A, 1990, P1981
[2]  
BUHLES WC, 1988, REV INFECT DIS S3, V10, P495
[3]  
BYRNE AK, 1992, 8 INT C AIDS 3 STD W
[4]   Application of the ''trimethyl lock'' to ganciclovir, a pro-prodrug with increased oral bioavailability [J].
Dillon, MP ;
Cai, HY ;
Maag, H .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (14) :1653-1656
[5]   ORAL GANCICLOVIR AS MAINTENANCE TREATMENT FOR CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS [J].
DREW, WL ;
IVES, D ;
LALEZARI, JP ;
CRUMPACKER, C ;
FOLLANSBEE, SE ;
SPECTOR, SA ;
BENSON, CA ;
FRIEDBERG, DN ;
HUBBARD, L ;
STEMPIEN, MJ ;
SHADMAN, A ;
BUHLES, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (10) :615-620
[6]   LOW-FREQUENCY MAINTENANCE GANCICLOVIR FOR CYTOMEGALOVIRUS RETINITIS [J].
HALL, AJH ;
JENNENS, ID ;
LUCAS, CR ;
MACLEAN, H ;
SANDLAND, AM .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1991, 23 (01) :43-46
[7]   DESIGN AND SYNTHESIS OF 6-FLUOROPURINE ACYCLONUCLEOSIDES - POTENTIAL PRODRUGS OF ACYCLOVIR AND GANCICLOVIR [J].
KIM, DK ;
KIM, HK ;
CHAE, YB .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1994, 4 (11) :1309-1312
[8]   Synthesis and evaluation of 2-amino-9-(3-hydroxymethyl-4-alkoxycarbonyloxybut-1-yl)purines as potential prodrugs of penciclovir [J].
Kim, DK ;
Lee, N ;
Kim, YW ;
Chang, KY ;
Kim, JS ;
Im, GJ ;
Choi, WS ;
Jung, IH ;
Kim, TS ;
Hwang, YY ;
Min, DS ;
Um, KA ;
Cho, YB ;
Kim, KH .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) :3435-3441
[9]  
LALCZARI JP, 1994, ANTIVIRAL RES S1, V23, P45
[10]   GANCICLOVIR FOR THE TREATMENT AND SUPPRESSION OF SERIOUS INFECTIONS CAUSED BY CYTOMEGALOVIRUS [J].
LASKIN, OL ;
CEDERBERG, DM ;
MILLS, J ;
ERON, LJ ;
MILDVAN, D ;
SPECTOR, SA .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (02) :201-207